Philadelphia, Denver — Global law firm Hogan Lovells advised Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium”), formerly known as Mind Medicine, on its US$805 million underwritten public offering of common shares, which included the full exercise of the underwriters’ option to purchase additional shares.
Definium is a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. On June 22, Definium announced positive topline results in its first Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
The company intends to use the net proceeds from the public offering for the research and development of its product candidates, preparation activities for potential commercialization of DT120 ODT, if approved, and working capital and general corporate purposes.
“We were thrilled to advise our long-standing client on this transaction, which underscores the continued strength and depth of our Life Sciences & Healthcare sector,” said Steve Abrams, partner and Global Co-Head Life Sciences & Health Care. “Our team’s ability to deliver strategic, cross-practice counsel reflects our deep industry knowledge and commitment to supporting clients at every stage of growth.”
The Hogan Lovells Capital Markets deal team was led by partner Steve Abrams (Philadelphia), with support from counsel Val Delp (Denver), senior associate Tyler Glass (Philadelphia), and associate Kayvon Stohler-Paul (Philadelphia). Additional cross-practice support was provided by senior counsel Henry Kahn (M&A, Baltimore), partners Steven Kaufman (M&A, Washington, D.C.), Caitlin Piper (Tax, Pensions & Benefits, Washington, D.C.), and Sally Gu (Pharmaceuticals and Biotechnology, Washington, D.C.), and associate Katherine Kramer (Pharmaceuticals and Biotechnology, Washington, D.C.).
More information about the transaction can be found here.
